ArticleAnnals of surgical oncology2020
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
Article in Annals of surgical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.Journal for immunotherapy of cancer · 2023Guideline
- Outcomes After Curative Metastasectomy for Patients with Malignant Melanoma: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2022Pooled it
- Immune checkpoint inhibitors plus debulking surgery for patients with metastatic renal cell carcinoma: clinical outcomes and immunological correlates of a prospective pilot trial.Nature communications · 2025Trial
- Salvage Metastasectomy After Adoptive Cell Transfer for Melanoma: Long-Term Updates.Annals of surgical oncology · 2026Article
- Invited Editorial about Article: "Salvage Metastasectomy after Adoptive Cell Transfer for Melanoma: Long-Term Updates" by Dinerman, Aaron et al.Annals of surgical oncology · 2026Article
- Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations.International journal of molecular sciences · 2026Review
- Thinking beyond immunotherapy: implementing a multimodal care plan to facilitate extended survival in stage IV melanoma.Melanoma research · 2026Article
- New Standards in the Treatment of Advanced Metastatic Melanoma: Immunotherapy and BRAF-Targeted Therapies as Emerging Paradigms.Current pharmaceutical design · 2026Review
- Metastatic Melanoma Outcomes and the Evolving Role of Surgery in the Immunotherapy Era.JAMA surgery · 2025Article
- Contemporary trends in utilization of metastasectomy in the era of targeted and immunotherapies.Cancer · 2025Article
- Safety outcomes and immunological correlates in a prospective clinical trial of immune checkpoint therapy plus debulking surgery for patients with metastatic renal cell carcinoma.Research square · 2024Article
- Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression.Liver cancer · 2024Article
- Unresectable cardiac metastasis from melanoma responds well to combination immunotherapy-a case report.European heart journal. Case reports · 2024Article
- Procedural interventions for oligoprogression during treatment with immune checkpoint blockade in gynecologic malignancies: a case series.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2024Article
- [Construction and Validation of Prediction Models of Risk Factors for Early Death in Patients With Metastatic Melanoma].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.European journal of cancer (Oxford, England : 1990) · 2024Article
- Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Series.The American journal of case reports · 2023Article
- Surgical Utilization and Outcomes for Patients with Stage IV Melanoma in the Modern Immunotherapy Era.Annals of surgical oncology · 2023Article
- Article
- Local Therapy for Oligoprogression or Consolidation in High Mutational Burden Stage 4 Colorectal Cancer Treated With PD-1 or PD-L1 Blockade.Annals of surgical oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
introductionCheckpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on to alternative treatments, including surgery, yet the outcome of patients selected for surgery after checkpoint blockade remains unclear.
methodsPatients who were treated with checkpoint blockade from 2003 to 2017, followed by metastasectomy, were identified from a prospectively maintained institutional melanoma database. Response to immunotherapy was assessed at the time of surgery. Patients were categorized as having responding, isolated progressing, or multiple progressing lesions.
resultsOf the 237 total patients identified, 208 (88%) had stage IV disease, and 29 (12%) had unresectable stage III disease at the start of immunotherapy. Median OS following first resection was 21 months. Median follow-up among survivors was 23 months. Complete resection at the first operation (n = 87, 37%) was associated with improved survival compared with patients with incomplete resection (n = 150, 63%) [median OS not reached (NR) vs. 10.8 months, respectively; 95% CI: 7.3, 14.8; p < 0.0001]. Patients resected for an isolated progressing or responding tumor had a longer median survival compared with those with multiple progressing lesions (NR vs. 7.8 months, 95% CI: 6.2, 11.2; p < 0.0001).
conclusionsPatients selected for surgical resection following checkpoint blockade have a relatively favorable survival, especially if they had a response to immunotherapy and undergo complete resection of isolated progressing or responding disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.